AstraZeneca: sells anti-psychotic drugs in Europe and Russia
(CercleFinance.com) - AstraZeneca continued its program of getting rid of old medicines on Wednesday, with the sale of anti-psychotic drugs Seroquel and Seroquel XR in Europe and Russia.
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel to Germany's Cheplapharm for an upfront payment of 178 million dollars.
Cheplapharmd may also make future sales-contingent payments of up to 61 million dollars, the drugmaker said.
Seroquel and Seroquel XR - which are primarily used to treat schizophrenia and bipolar disorder - have lost their patent protection in Europe and Russia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel to Germany's Cheplapharm for an upfront payment of 178 million dollars.
Cheplapharmd may also make future sales-contingent payments of up to 61 million dollars, the drugmaker said.
Seroquel and Seroquel XR - which are primarily used to treat schizophrenia and bipolar disorder - have lost their patent protection in Europe and Russia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.